FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention refers to pharmaceutical industry, namely to a pharmaceutical composition for treating tumours. Pharmaceutical composition for treating tumours contains: (a) of at least 2x109 PFU/ml of parvovirus H1 (H-1PV) or related rodent parvovirus specified in a group consisting of LuIII virus, small virus of mice (MMV), parvovirus mice (MPV), small rat virus (RMV), rat parvovirus or rat virus (RV), and (b) a pharmaceutically acceptable carrier containing 40–50 % of iodixanol wt/volume, 0.7–0.9 mmol of CaCl2 x 2 H2O, 50–60 mmol of NaCl, 0.9–1.2 mmol of KCl, 0.7–0.95 mg/ml of tromethamine and 0.05–0.15 mg/ml of sodium edetate calcium.
EFFECT: composition described above has stability during storage.
5 cl, 7 dwg, 1 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DIAGNOSTIC COMPOSITION CONTAINING BLOOD PLASMA CATIONS AND POSSESSING EXCELLENT SAFETY PROFILE | 2010 |
|
RU2544113C2 |
| TREATMENT OF CANCER BY PARVOVIRUS IN COMBINATION WITH BEVACIZUMAB | 2016 |
|
RU2679442C1 |
| METHOD OF OPTIMIZING LARGE-SCALE PRODUCTION OF PARVOVIRUS H-1 IN SUBSTANTIALLY SERUM-FREE MEDIUM | 2017 |
|
RU2714111C1 |
| HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS FOR USE AGAINST CANCER AND VIRAL INFECTIONS | 2015 |
|
RU2766087C2 |
| METHOD AND REAGENT FOR PREPARING A DIAGNOSTIC COMPOSITION | 2014 |
|
RU2662319C2 |
| N,N'-DIACETYLCYSTINE ORGANIC SALTS, METHODS OF THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT | 1992 |
|
RU2135468C1 |
| COMPOSITION AND METHOD FOR PRODUCTION OF ENHANCED STABILITY MEDICATIONS SLIGHTLY SOLUBLE IN WATER | 2006 |
|
RU2451510C2 |
| COMPLEX FOR ENHANCING IMMUNE RESPONSE | 2019 |
|
RU2779622C2 |
| COMPOSITIONS, INCLUDING POORLY SOLUBLE IN WATER PHARMACEUTIC SUBSTANCES AND ANTIMICROBIAL SUBSTANCES | 2006 |
|
RU2433818C2 |
| QUINAZOLINE COMPOUNDS | 2011 |
|
RU2530887C2 |
